Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Leukemia 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

Cyclophosphamide 48fludarabine phosphate 36Methotrexate 26Cytarabine 24fludarabine 23Whole-Body Irradiation 23Rituximab 19Cyclosporine 19Antilymphocyte Serum 18Peripheral Blood Stem Cell Transplantation 17Filgrastim 17Busulfan 17Mycophenolic Acid 16Tacrolimus 15Azacitidine 15Alemtuzumab 15Radiotherapy 13Melphalan 13Imatinib Mesylate 13Etoposide 13Vincristine 11Methylprednisolone 11Cord Blood Stem Cell Transplantation 11Dexamethasone 10venetoclax 8Granulocyte Colony-Stimulating Factor 8Clofarabine 8thymoglobulin 7sargramostim 7nilotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia × Interleukin-15 × Clear all
NCT03759184 2022-03-22

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 13 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡